Sökning: WFRF:(Cuttano Roberto) > (2015) > Sulindac metabolite...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04091naa a2200505 4500 | |
001 | oai:DiVA.org:uu-259652 | |
003 | SwePub | |
008 | 150810s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2596522 URI |
024 | 7 | a https://doi.org/10.1073/pnas.15013521122 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bravi, Luca4 aut |
245 | 1 0 | a Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice |
264 | c 2015-06-24 | |
264 | 1 | b Proceedings of the National Academy of Sciences,c 2015 |
338 | a print2 rdacarrier | |
500 | a This study was supported by grants (to E.D.) from TELETHON-GGP14149, Associazione Italiana per la Ricerca sul Cancro (AIRC) (AIRC IG 14471), "Special Program Molecular Clinical Oncology 5x1000" to AIRC-Gruppo Italiano Malattie Mieloproliferative, Fondazione Cassa di Risparmio delle Provincie Lombarde (CARIPLO) Contract 2012-0678, the European Community (Wnt for Brain Contract 268870; Innovative Training Networks Vessel 317250, Endostem-Health-2009-241440), and Fondazione CARIPLO Contract 2014-1038 (to N.R.). R.C. was supported by the FIRC fellowship 16617. Part of this work was funded by the European consortium European Research Area Network NEURON (to E.T.-L.).Dejana E and Lampugnani MG share the last authorship and corresponding. | |
520 | a Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of beta-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a beta-catenin-driven transcription program that leads to endothelial-tomesenchymal transition. TGF-beta/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate beta-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Annan medicin och hälsovetenskapx Övrig annan medicin och hälsovetenskap0 (SwePub)305992 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Other Medical and Health Sciencesx Other Medical and Health Sciences not elsewhere specified0 (SwePub)305992 hsv//eng |
653 | a cerebral cavernous malformation | |
653 | a endothelial cells | |
653 | a beta-catenin | |
653 | a sulindac metabolites | |
653 | a vascular pathology | |
700 | 1 | a Rudini, Noemi4 aut |
700 | 1 | a Cuttano, Roberto4 aut |
700 | 1 | a Giampietro, Costanza4 aut |
700 | 1 | a Maddaluno, Luigi4 aut |
700 | 1 | a Ferrarini, Luca4 aut |
700 | 1 | a Adams, Ralf H.4 aut |
700 | 1 | a Corada, Monica4 aut |
700 | 1 | a Boulday, Gwenola4 aut |
700 | 1 | a Tournier-Lasserve, Elizabeth4 aut |
700 | 1 | a Dejana, Elisabettau Uppsala universitet,Vaskulärbiologi4 aut0 (Swepub:uu)elide443 |
700 | 1 | a Lampugnani, Maria Grazia4 aut |
710 | 2 | a Uppsala universitetb Vaskulärbiologi4 org |
773 | 0 | t Proceedings of the National Academy of Sciences of the United States of Americad : Proceedings of the National Academy of Sciencesg 112:27, s. 8421-8426q 112:27<8421-8426x 0027-8424x 1091-6490 |
856 | 4 | u https://www.pnas.org/content/pnas/112/27/8421.full.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-259652 |
856 | 4 8 | u https://doi.org/10.1073/pnas.1501352112 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy